HGH Fragment 176-191

hGH 176-191, Frag 176-191, Growth Hormone Fragment 176-191

A synthetic peptide derived from human growth hormone that promotes fat loss by stimulating lipolysis and inhibiting lipogenesis without growth effects.

Molecular Profile

Formula C₇₈H₁₂₃N₂₃O₂₃S₂

Mol. Weight 1815.1 g/mol

Sequence Gly-Glu-Pro-Pro...

Clinical Data Trials

Scientific Data Studies

Route	Dosage	Bioavailability
Subcutaneous (SC) 200-500 mcg, 1-3 times daily	200-500 mcg, 1-3 times daily	High (95%)	SUB
Oral 1-5 mg	1-5 mg	Low (5%)	ORA

How It Works

How It Works: HGH Fragment 176-191 mimics the fat-regulating properties of growth hormone's C-terminus, selectively targeting adipose tissue to reduce body fat.

Lipolysis Stimulation: Activates hormone-sensitive lipase to break down stored triglycerides into free fatty acids and glycerol.
Lipogenesis Inhibition: Suppresses the activity of enzymes involved in fat synthesis, preventing new fat accumulation.
Fat Oxidation Enhancement: Promotes the beta-oxidation of fatty acids in mitochondria for energy production.
Metabolic Specificity: Avoids insulin resistance or growth promotion by not interacting with full GH receptors.

Pairs Well With

Latest Clinical Trials

See All Clinical Trials

Active Not Recruiting PHASE3 NCT03755791

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy

Exelixis

INTERVENTIONAL

Updated Dec 15, 2025

View All Clinical Trials

Latest Studies

See All Studies

Utility 1

pubmed Jun 27, 2022

Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells.

Habibullah. Mahmoud M MM; Mohan. Syam S; Syed. Nabeel Kashan NK; Makeen. Hafiz A...

Scientists packed a short piece of human growth hormone (the 176‑191 fragment) together with the chemotherapy drug doxorubicin inside tiny chitosan particles. In lab tests on breast cancer cells, this combo killed more cancer cells than doxorubicin alone, likely because the peptide helped the drug stick better to cancer‑related proteins.

Utility 2

pubmed 1978

Hyperglycemic action of synthetic C-terminal fragments of human growth hormone.

Ng. F M FM; Bornstein. J J

In rats, short pieces of human growth hormone that include the 176‑191 region cause a quick spike in blood sugar and a longer increase in insulin, and they make the animals less sensitive to insulin. Two nearby fragments (179‑191 and 180‑191) did nothing. The effect only shows up when the peptide has the right sequence and shape.

Browse All Studies